Clinical Trials in China / NCT05805007
Recruiting
Early Phase 1
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
NCT05805007 · tracked via the Priya Life Science China tracker
Condition(s) studied
Retinitis Pigmentosa
Investigational drug(s) / intervention(s)
ZVS203e: ZVS203e is a rAAV-mediated gene editing drug that silences RHO mutant protein expression by CRISPR/Cas9 editing system.
Study summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of ZVS203e administered via subretinal injection in participants with RP caused by RHO site-specific gene mutation (RHO-RP). This is a single-arm, open-label, single ascending dose study.
Eligibility
Inclusion Criteria:
* 1\. Patients with clinical diagnosis of Retinitis Pigmentosa (RP) (age ≥ 18 years) ;
* 2\. Genetic test confirmed to carry a fix mutation of RHO and carry no pathogenic mutations of other ophthalmic genetic diseases;
* 3\. Meet the following target eye selection criteria： Best corrected visual acuity between 2.3 LogMAR and 0.5 LogMAR (including 2.3 LogMAR and 0.5 LogMAR, equivalent to Snellen visual acuity of hand move to 20/63) ;
* 4\. Agree to take effective contraceptive measures from the beginning of the study to 1 year after the administration;
* 5.Willingness to adhere to protocol as evidenced by written informed consent;
* Definition of the study eye: The study eye is defined as the eye with worse visual acuity between the two eyes of each prospective subject. For all subjects, only one eye shall be designated as the "study eye" (i.e., the eye receiving treatment). If both eyes of a patient meet the eligibility criteria and have equal visual acuity, the investigator shall determine the study eye based on clinical judgment.
Exclusion Criteria:
* 1\. Existing or pre-existing of macular lesions such as retinoschisis or macular membrane, or other eye conditions interfering with the surgery or the interpretation of the clinical endpoint, in the investigators' opinion;
* 2\. The study eye has been treated with other drugs within 3 months that could affect the evaluation of the investigational drug;
* 3\. The study eye has been treated with the following intraocular procedures: retinal detachment surgery, vitrectomy;
* 4\. The presence of an ocular/visual disease, disorder or lesion known to cause, or to be associated with, vision loss, or whose associated treatment or therapy is known to cause, or to be associated with, vision loss；
* 5\. Currently taking or may require systemic medications that can cause ocular toxicity, such as psoralen, risedronate, or tamoxifen;
* 6\. Known allergy to the drug planned for use in the study；
* 7.Those with the following laboratory abnormalities which are clinically significant: Liver function: chronic liver disease, ALT increased \>2 times the upper limit of normal; With uncontrolled hypertension, mean systolic blood pressure ≥ 160 mmHg or mean diastolic blood pressure ≥ 100 mmHg; With uncontrolled diabetes, HbA1c\>10%; Patients with abnormal coagulation function (prothrombin time ≥ upper limit of normal (3 seconds' longer), activated partial thromboplastin time ≥ upper limit of normal (10 seconds' longer)); Serum virology test: Active hepatitis B, hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab) or syphilis antibody positive;
* 8\. Having any past or present medical history that may affect the safety of the trial or the in vivo process of the drug, especially the medical history of cardiovascular, hepatic, renal, endocrine, gastrointestinal, pulmonary, neurological, hematological, oncologic, immunological or metabolic disorders and others that are thought clinically significant by the investigator；
* 9\. Participation in any medicine or medical device clinical trials within 3 months prior to enrollment;
* 10\. Neutralizing antibodies to rAAV\> 1:1000 by immunologic test;
* 11\. For females in pregnancy or lactation period;
* 12\. Any other conditions which leads the investigator to determine the participant is unsuitable for this study.
Primary outcome measure(s)
- AEs and SAEs — Baseline up to Week 52
Type, severity, and incidence of ocular and systemic adverse events (AEs) and serious adverse events (SAEs) in the study eye after ZVS203e administration. - Immunogenicity Testing — Baseline up to Week 52
Immunogenicity following subretinal administration of ZVS203e injection, including T-cell immune responses against SauriCas9 and AAV8, and titers of anti-SauriCas9 binding antibodies, anti-AAV8 binding antibodies, and anti-AAV8 neutralizing antibodies. - Vector Shedding — Baseline up to Week 52
Vector DNA shedding in blood and tears following subretinal administration of ZVS203e injection.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Peking University Third Hospital | Beijing | Beijing Municipality | Recruiting |
More Peking University Third Hospital trials in China
Shared Medical Appointment for COPD Patients (SMA-COPD)
Active, not recruiting
Other trials for the same condition
Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05805007 on ClinicalTrials.gov ↗ ← All trials in China